Document 0603
 DOCN  M9650603
 TI    [Therapeutic approaches in diseases caused by mycobacteria]
 DT    9605
 AU    Urbanczik R; Med.-diagnostisches Institut der Fatol Arzneimittel GmbH,;
       Schiffweiler.
 SO    Pneumologie. 1995 Dec;49 Suppl 3:649-52. Unique Identifier : AIDSLINE
       MED/96147391
 AB    Following the historical introduction (the review by Schlossberger,
       1928) the evolution of individual chemotherapy phases is briefly
       discussed. Then after following points are discussed. 1) The usual
       controlled clinical trials for evaluation of new drugs must be replaced
       (perhaps by estimates of the early bactericidal activity and of the 2
       months' sputum conversion rates). 2) Interesting and of importance are
       research activities connected with the reasons for properties of TB
       bacilli in the persistence state, and of drugs capable to combat such
       bacilli (metronidazole?). 3) Since the human immunity against TB
       normally operates well (from 100 infected approximately 10 will get a
       clinically manifest disease), it is necessary to investigate possible
       combinations of chemo- and immunotherapy, either of combinations of
       antituberculous and immunomodulating drugs (eg. TNF alpha-antagonists),
       or of chemotherapy combined with vaccination (eg. M. vaccae). 4) There
       are still unsolved problems in formulations of drugs (particularly R in
       fixed combinations) and of drug resorption (in HIV-pos. patients). 5)
       Other points of research interest could be the adsorption of TB bacilli
       on the surface of mammalian cells (1st step in pathogenesis), drugs
       other than antituberculotics (eg. amoxycillin + clavulanic acid), or
       even drugs used for completely other diseases (eg. antidepressive). 6)
       All these attempts should serve primarily the purpose of further
       reduction of the necessary therapy duration (M+ pulmonary TB) to 1 - 2
       months in total.
 DE    Antitubercular Agents/ADVERSE EFFECTS/*THERAPEUTIC USE  AIDS-Related
       Opportunistic Infections/*DRUG THERAPY  Drug Therapy, Combination
       English Abstract  Human  Microbial Sensitivity Tests  Mycobacterium
       tuberculosis/DRUG EFFECTS  Mycobacterium Infections, Atypical/*DRUG
       THERAPY  Tuberculosis, Pulmonary/*DRUG THERAPY  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).